公开(公告)号：US20080254140A1

公开(公告)日：2008-10-16

申请号：US11659915

申请日：2005-08-18

申请人： Kenneth Widder ,  Jay Lichter

发明人： Kenneth Widder ,  Jay Lichter

IPC分类号： A61K33/34 ,  A61K31/164 ,  A61K31/215 ,  A61K31/095 ,  A61K31/12 ,  A61K33/30 ,  A61K31/66 ,  A61P27/02 ,  A61K33/04 ,  A61K31/122 ,  A61K31/445 ,  A61K31/355 ,  A61K36/45

CPC分类号： A61K45/06 ,  A61K31/10 ,  A61K31/165 ,  A61K31/203 ,  A61K31/216 ,  A61K2300/00

摘要： Described herein are combination methods, compositions and therapies for treating ophthalmic conditions or diseases arising from, associated with or leading to the overproduction of waste products in the visual cycle. Agents included within these combinations are 13-cis-retinyl derivatives; other agents included within these combinations are selected from vitamins, antioxidants, minerals, inducers of nitric oxide production, anti-inflammatory agents, and negatively-charged phospholipids. Such combination methods may be used as single or multiple administration therapies, or in combination with other agents or therapies.

摘要翻译： 本文描述了用于治疗眼睛疾病或由视觉循环引起的与过量产生的过度生成相关或引起的疾病的组合方法，组合物和疗法。 包含在这些组合中的药剂是13-顺式 - 视黄酯衍生物; 包括在这些组合中的其它药剂选自维生素，抗氧化剂，矿物质，一氧化氮产生的诱导剂，抗炎剂和带负电荷的磷脂。 这种组合方法可以用作单次或多次给药疗法，或与其它药物或疗法组合使用。

公开(公告)号：US08314152B2

公开(公告)日：2012-11-20

申请号：US11150641

申请日：2005-06-10

申请人： Kenneth Widder ,  Jay Lichter ,  Nathan L. Mata

发明人： Kenneth Widder ,  Jay Lichter ,  Nathan L. Mata

IPC分类号： A01N33/18 ,  A01N33/24 ,  A61K31/12

CPC分类号： A61K31/167 ,  A61K31/16 ,  A61K31/215 ,  G01N2800/164

摘要： Compounds that cause reversible night blindness may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions. Such compounds and their derivatives may be used as single agent therapy or in combination with other agents or therapies.

摘要翻译： 引起可逆性夜盲症的化合物可用于治疗与视觉循环过程中积累的废物过量生产相关的眼科疾病。 我们描述使用这些化合物及其衍生物治疗例如黄斑变性和营养不良的方法和组合，或减轻与这种眼科疾病相关的症状。 这些化合物及其衍生物可以用作单一药物治疗或与其它药物或疗法组合使用。

公开(公告)号：US20120238632A1

公开(公告)日：2012-09-20

申请号：US13231890

申请日：2011-09-13

申请人： Nathan L. Mata ,  Yun Han ,  Kenneth Widder ,  Jay Lichter

发明人： Nathan L. Mata ,  Yun Han ,  Kenneth Widder ,  Jay Lichter

IPC分类号： A61K31/167 ,  A61P27/02

CPC分类号： G01N33/6893 ,  A61K31/16 ,  A61K31/203 ,  A61K31/215 ,  A61K41/0061 ,  A61K49/0041 ,  A61K49/0052 ,  A61K49/0056 ,  G01N33/542 ,  G01N2500/02 ,  G01N2800/164 ,  Y10S514/912 ,  A61K2300/00

摘要： Described herein are methods and compositions for the detection of transthyretin (TTR), retinol binding protein (RBP) and retinol complex formation. The methods and compositions described herein also provide for the screening of modulators of retinol-RBP-TTR complex formation. Furthermore, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies.

摘要翻译： 本文描述了用于检测转甲状腺素蛋白（TTR），视黄醇结合蛋白（RBP）和视黄醇复合物形成的方法和组合物。 本文所述的方法和组合物还提供了视黄醇-RBP-TTR复合物形成的调节剂的筛选。 此外，所述方法和组合物提供用于治疗和/或预防年龄相关性黄斑变性和/或营养不良症的治疗剂。

公开(公告)号：US20120202885A1

公开(公告)日：2012-08-09

申请号：US13118207

申请日：2011-05-27

申请人： Kenneth Widder ,  Jay Lichter

发明人： Kenneth Widder ,  Jay Lichter

IPC分类号： A61K31/167 ,  A61P27/02

CPC分类号： A61K31/165 ,  A61K31/16 ,  A61K31/56 ,  A61K45/06 ,  G01N2800/042 ,  G01N2800/164 ,  A61K2300/00

摘要： Described herein are methods and compositions for treating certain retinol-related diseases and conditions by modulation of transthyretin (TTR) and retinol binding protein (RBP) availability in the subject. For example, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies, metabolic disorders, idiopathic intracranial hypertension, hyperostosis, and protein misfolding and aggregation diseases. The compositions disclosed may be used as single agent therapy or in combination with other agents or therapies. In addition, described herein are methods and assays for selecting appropriate agents that can modulate the TTR and RBP availability in a subject.

公开(公告)号：US20060135460A1

公开(公告)日：2006-06-22

申请号：US11296909

申请日：2005-12-08

申请人： Kenneth Widder ,  Jay Lichter

发明人： Kenneth Widder ,  Jay Lichter

IPC分类号： A61K48/00 ,  A61K31/56 ,  A61K31/16

CPC分类号： A61K31/165 ,  A61K31/16 ,  A61K31/56 ,  A61K45/06 ,  G01N2800/042 ,  G01N2800/164 ,  A61K2300/00

摘要： Described herein are methods and compositions for treating certain retinol-related diseases and conditions by modulation of transthyretin (TTR) and retinol binding protein (RBP) availability in the subject. For example, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies, metabolic disorders, idiopathic intracranial hypertension, hyperostosis, and protein misfolding and aggregation diseases. The compositions disclosed may be used as single agent therapy or in combination with other agents or therapies. In addition, described herein are methods and assays for selecting appropriate agents that can modulate the TTR and RBP availability in a subject.

摘要翻译： 本文描述了通过调节受试者中转甲状腺素蛋白（TTR）和视黄醇结合蛋白（RBP）可用性来治疗某些视黄醇相关疾病和病症的方法和组合物。 例如，该方法和组合物提供用于治疗和/或预防年龄相关性黄斑变性和/或营养不良，代谢紊乱，特发性颅内高血压，增生性骨折和蛋白质错折叠和聚集疾病的治疗剂。 所公开的组合物可用作单一药物治疗或与其它药物或疗法组合使用。 此外，本文描述了用于选择可以调节受试者的TTR和RBP可用性的适当试剂的方法和测定法。

公开(公告)号：US20060058355A1

公开(公告)日：2006-03-16

申请号：US11209463

申请日：2005-08-23

申请人： Howard Dittrich ,  Lauren Otsuki ,  Kenneth Widder

发明人： Howard Dittrich ,  Lauren Otsuki ,  Kenneth Widder

IPC分类号： A61K31/455 ,  A61K31/4439

CPC分类号： A61K31/4164 ,  A61K31/401 ,  A61K31/44 ,  A61K31/4422 ,  A61K31/4439 ,  A61K31/455 ,  A61K45/06 ,  A61K2300/00

摘要： Disclosed is a pharmaceutical composition comprising a calcium channel blocker and an angiotensin II receptor blocker or an angiotensin converting enzyme inhibitor. Also disclosed is a method of treating cardiovascular disease or renal disease comprising identifying a patient in need of such treatment, and administering a pharmaceutical composition disclosed herein to said patient.

摘要翻译： 公开了包含钙通道阻滞剂和血管紧张素II受体阻断剂或血管紧张素转化酶抑制剂的药物组合物。 还公开了治疗心血管疾病或肾脏疾病的方法，其包括鉴定需要这种治疗的患者，以及将本文公开的药物组合物给予所述患者。

公开(公告)号：US20060035911A1

公开(公告)日：2006-02-16

申请号：US11248905

申请日：2005-10-11

申请人： Kenneth Widder ,  Lauren Otsuki ,  Howard Dittrich ,  Scott Thomson ,  Roland Blantz

发明人： Kenneth Widder ,  Lauren Otsuki ,  Howard Dittrich ,  Scott Thomson ,  Roland Blantz

IPC分类号： A61K31/549 ,  A61K31/522

CPC分类号： A61K45/06 ,  A61K31/405 ,  A61K31/522 ,  A61K31/63 ,  A61K31/635 ,  A61K2300/00

摘要： Disclosed is a pharmaceutical composition comprising a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, and a non-adenosine modifying diuretic. Also disclosed are methods of inducing a diuretic effect in an animal comprising the step of administering a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, in combination with second pharmaceutical composition capable of inducing a diuretic effect.

公开(公告)号：US20050004145A1

公开(公告)日：2005-01-06

申请号：US10830617

申请日：2004-04-23

申请人： Kenneth Widder ,  Lauren Otsuki ,  Howard Dittrich ,  Scott Thomson ,  Roland Blantz

发明人： Kenneth Widder ,  Lauren Otsuki ,  Howard Dittrich ,  Scott Thomson ,  Roland Blantz

IPC分类号： A61K31/405 ,  A61K31/522 ,  A61K31/63 ,  A61K31/635 ,  A61K45/06 ,  A61P7/10

CPC分类号： A61K45/06 ,  A61K31/405 ,  A61K31/522 ,  A61K31/63 ,  A61K31/635 ,  A61K2300/00

摘要： Disclosed is a pharmaceutical composition comprising a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, and a non-adenosine modifying diuretic. Also disclosed are methods of inducing a diuretic effect in an animal comprising the step of administering a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, in combination with second pharmaceutical composition capable of inducing a diuretic effect.

摘要翻译： 公开了包含治疗有效量的KW-3902或其盐，酯，酰胺，代谢物或前药以及非腺苷改性利尿剂的药物组合物。 还公开了在动物中诱导利尿作用的方法，包括施用治疗有效量的KW-3902或其盐，酯，酰胺，代谢物或前药与能够诱导 利尿作用。

公开(公告)号：US20090253665A1

公开(公告)日：2009-10-08

申请号：US12485797

申请日：2009-06-16

申请人： Lauren Otsuki ,  Kenneth Widder ,  Howard C. Dittrich

发明人： Lauren Otsuki ,  Kenneth Widder ,  Howard C. Dittrich

IPC分类号： A61K31/585 ,  A61K31/522 ,  A61P9/00 ,  A61P13/12 ,  A61P9/04 ,  A61P9/12 ,  A61P9/10

CPC分类号： A61K31/437 ,  A61K31/4745 ,  A61K31/522 ,  A61K31/56 ,  A61K31/585 ,  A61K45/06 ,  A61K2300/00

摘要： Pharmaceutical compositions comprising an aldosterone inhibitor and an adenosine A1 receptor antagonist (AA1RA) and methods of treating cardiovascular disease comprising identifying a patient in need of such treatment, and administering a pharmaceutical composition disclosed herein to said patient are disclosed.

摘要翻译： 公开了包含醛固酮抑制剂和腺苷A1受体拮抗剂（AA1RA）的药物组合物和治疗心血管疾病的方法，包括鉴定需要这种治疗的患者，以及向所述患者施用本文公开的药物组合物。

公开(公告)号：US20060030572A1

公开(公告)日：2006-02-09

申请号：US11248479

申请日：2005-10-11

申请人： Kenneth Widder ,  Lauren Otsuki ,  Howard Dittrich ,  Scott Thomson ,  Roland Blantz

发明人： Kenneth Widder ,  Lauren Otsuki ,  Howard Dittrich ,  Scott Thomson ,  Roland Blantz

IPC分类号： A61K31/549 ,  A61K31/522

CPC分类号： A61K45/06 ,  A61K31/405 ,  A61K31/522 ,  A61K31/63 ,  A61K31/635 ,  A61K2300/00

摘要： Disclosed is a pharmaceutical composition comprising a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, and a non-adenosine modifying diuretic. Also disclosed are methods of inducing a diuretic effect in an animal comprising the step of administering a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, in combination with second pharmaceutical composition capable of inducing a diuretic effect.